Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of LV20.19 CAR T-cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

NCT05990465 is registered in ClinicalTrials.gov with Medical College of Wisconsin as lead sponsor.

NCT NCT05990465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05990465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of LV20.19 CAR T-cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Lead sponsor
Medical College of Wisconsin
Phase
Phase 1
Overall status
Recruiting
Start date
February 6, 2025
Completion date
July 31, 2030
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

burkitt lymphoma, diffuse large b cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, non hodgkin lymphoma